Strategic Collaboration Agreement: Harbour BioMed has entered into a global strategic collaboration with Bristol Myers Squibb to accelerate the discovery and development of multi-specific antibodies, potentially receiving up to $90 million in initial payments and up to $1.035 billion in development and commercial milestone payments.
Technological Platform Advantage: This collaboration leverages the Harbour Mice® technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential, thereby strengthening the company's competitive edge in antibody therapeutics.
Accelerated Clinical Trials: The partnership will also utilize Harbour BioMed's development capabilities in China to conduct early clinical trials, expediting program progress and addressing global patient needs, reflecting the company's strategic positioning in international markets.
Broad Market Prospects: By collaborating with Bristol Myers Squibb, Harbour BioMed not only expands its product pipeline but also benefits from the latter's expertise in drug discovery and development, driving the launch of transformative therapies and further solidifying its position in the biopharmaceutical industry.
02142
$12.93+Infinity%1D
Analyst Views on 02142
Wall Street analysts forecast 02142 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02142 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 02142 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02142 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 12.840
Low
Averages
High
Current: 12.840
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
